Idiopathic Pulmonary Fibrosis News and Research RSS Feed - Idiopathic Pulmonary Fibrosis News and Research

Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

InterMune, Inc. today announced that the Board of the Italian Drug Agency has approved the pricing and reimbursement conditions for Esbriet (pirfenidone), and that the agreement has been published in the Official Gazette, the official journal of the government of Italy. [More]
PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing. [More]
MUC5B gene variation improves survival in patients with idiopathic pulmonary fibrosis

MUC5B gene variation improves survival in patients with idiopathic pulmonary fibrosis

Variation in the gene MUC5B among patients with idiopathic pulmonary fibrosis was associated with improved survival, according to a study published online by JAMA. The study is being released early online to coincide with its presentation at the American Thoracic Society international conference. [More]
Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society International Conference in Philadelphia, Pennsylvania. [More]
Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22. [More]
Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete. [More]
Study identifies seven new genetic regions associated with pulmonary fibrosis

Study identifies seven new genetic regions associated with pulmonary fibrosis

A new genome-wide association study of more than 6,000 people has identified seven new genetic regions associated with pulmonary fibrosis. In findings published online in Nature Genetics on April 14, 2013, researchers at National Jewish Health, the University of Colorado and several other institutions found a number of genes associated with host defense, cell-cell adhesion and DNA repair, which provide clues to possible mechanisms underlying this currently untreatable disease. [More]
Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that was linked to an increase in the risk of death. [More]
Study finds genetic variation is associated with pulmonary fibrosis risk

Study finds genetic variation is associated with pulmonary fibrosis risk

A newly published study of patients with pulmonary fibrosis has discovered multiple genetic variations that should help with future efforts to treat the disease. [More]
New study examines role of mast cells in development of idiopathic pulmonary fibrosis

New study examines role of mast cells in development of idiopathic pulmonary fibrosis

Pulmonary fibrosis is a chronic, deadly disease that affects five million people worldwide. It is irreversible, its cause is poorly understood, and it has a median survival of only about 3 years. [More]
Scientists identify potential treatment for idiopathic pulmonary fibrosis

Scientists identify potential treatment for idiopathic pulmonary fibrosis

Investigators at the University of Alabama at Birmingham (UAB) have unlocked another piece of the puzzle surrounding idiopathic pulmonary fibrosis, an often fatal lung disease with no cure and no effective treatments. [More]
CPF and PFF to partner with ATS to fund pulmonary fibrosis research

CPF and PFF to partner with ATS to fund pulmonary fibrosis research

The Coalition for Pulmonary Fibrosis, the Pulmonary Fibrosis Foundation, and the American Thoracic Society-the world's leading professional organization for pulmonary, critical care and sleep medicine-today announced that the CPF and the PFF will again partner with the ATS to fund pulmonary fibrosis research. [More]
New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Tiotropium delivered once daily via Respimat significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS/LABA, irrespective of their allergic status. [More]
LASAG trial for severe influenza initiated

LASAG trial for severe influenza initiated

... [More]

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H). [More]
Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

Chinese herbs, including JHQG, BFXL, and BFHX, may show significant benefits for patients with non-small cell lung cancer (NSCLC), idiopathic pulmonary fibrosis (IPF), and influenza. [More]
New nanodevice lays foundations for future development of novel therapies against aging

New nanodevice lays foundations for future development of novel therapies against aging

A team of Spanish scientists has developed an intelligent nanodevice that lays the foundations for the future development of new therapies against aging. The device consists of nanoparticles that can selectively release drugs in aged human cells. [More]
InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

InterMune, Inc. today announced that Health Canada has approved Esbriet (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in adult patients. [More]
Coalition for Pulmonary Fibrosis announces winners of 2012 annual awards for distinguished service

Coalition for Pulmonary Fibrosis announces winners of 2012 annual awards for distinguished service

The Coalition for Pulmonary Fibrosis (CPF) proudly announces the winners of its three annual awards for distinguished service. Each honoree has made vital contributions to the effort to fight Pulmonary Fibrosis (PF) – in research, humanitarian and advocacy efforts. [More]
Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose. [More]
Advertisement
Advertisement